-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HYYsBov5QgMcbH7fJzoeevwYNen67sAt5dwQJsrlTcCNgSYG0R2MiORzhDBAjCqU 6vt2i1l6ctNyyzkJtCLSaQ== 0000950134-08-005181.txt : 20080321 0000950134-08-005181.hdr.sgml : 20080321 20080321070453 ACCESSION NUMBER: 0000950134-08-005181 CONFORMED SUBMISSION TYPE: SC 14D9/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080321 DATE AS OF CHANGE: 20080321 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LIFECORE BIOMEDICAL INC CENTRAL INDEX KEY: 0000028626 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 410948334 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 14D9/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-35300 FILM NUMBER: 08704127 BUSINESS ADDRESS: STREET 1: 3515 LYMAN BLVD CITY: CHASKA STATE: MN ZIP: 55318-3051 BUSINESS PHONE: 6123684300 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC INC DATE OF NAME CHANGE: 19861214 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN MEDICAL RESEARCH INC DATE OF NAME CHANGE: 19691118 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: LIFECORE BIOMEDICAL INC CENTRAL INDEX KEY: 0000028626 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 410948334 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 14D9/A BUSINESS ADDRESS: STREET 1: 3515 LYMAN BLVD CITY: CHASKA STATE: MN ZIP: 55318-3051 BUSINESS PHONE: 6123684300 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC INC DATE OF NAME CHANGE: 19861214 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN MEDICAL RESEARCH INC DATE OF NAME CHANGE: 19691118 SC 14D9/A 1 c25111sc14d9za.htm AMENDMENT NO.2 TO SOLICITATION/RECOMMENDATION STATEMENT sc14d9za
Table of Contents

 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT UNDER
SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
 
Lifecore Biomedical, Inc.
(Name of Subject Company)
Lifecore Biomedical, Inc.
(Name of Persons Filing Statement)
Common Shares
(Title of Class of Securities)
532187101
(CUSIP Number of Class of Securities)
Dennis J. Allingham
Lifecore Biomedical, Inc.
3515 Lyman Boulevard
Chaska, Minnesota 55318
(952) 368-4300
(Name, address and telephone numbers of person authorized to receive notices
and communications on behalf of the persons filing statement)
Copies to:
Robert A. Rosenbaum
Dorsey & Whitney LLP
50 South Sixth Street, Suite 1500
Minneapolis, Minnesota 55402
(612) 340-2600
    o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
 
 

 

TABLE OF CONTENTS

ITEM 8. ADDITIONAL INFORMATION
ITEM 9. EXHIBITS
SIGNATURES
INDEX TO EXHIBITS

Table of Contents

     This Amendment No. 2 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 filed by Lifecore Biomedical, Inc. (the “Company”) with the Securities Exchange Commission (the “SEC”) on February 21, 2008, as amended by Amendment No. 1 thereto filed with the SEC on February 26, 2008 (collectively, the “Statement”). The Statement relates to the cash tender offer by SBT Acquisition Inc., a Minnesota corporation (the “Purchaser”) and wholly owned subsidiary of SBT Holdings Inc., a Delaware corporation (the “Parent”), disclosed in a Tender Offer Statement on Schedule TO dated February 21, 2008, filed with the SEC, to purchase all of the outstanding shares of the Company’s common stock (the “Shares”) at a price of $17.00 per share, net to the seller in cash, without interest and less any required withholding taxes, if any, upon the terms and subject to the conditions set forth in the Offer to Purchase dated February 21, 2008 (the “Offer”), and the related Letter of Transmittal. Copies of the Offer and the Letter of Transmittal were filed as Exhibits (a)(1) and    (a)(2) to the Statement, respectively, and are incorporated herein by reference. Except as otherwise indicated herein, the information set forth in the Statement remains unchanged.
     The information in the Statement is incorporated in this Amendment by reference, except that such information is hereby amended and supplemented to the extent specifically provided herein.
ITEM 8. ADDITIONAL INFORMATION
     Item 8 is hereby amended and supplemented by adding the following text to the end thereof:
Expiration and Completion of Offer
     The Offer expired at 5:00 p.m., New York City time, on March 20, 2008. All of the conditions to the Offer have been satisfied. Accordingly, on March 20, 2008, Purchaser accepted for payment in accordance with the terms of the Offer all Shares that were validly tendered and not withdrawn prior to expiration of the Offer (including all Shares delivered through notices of guaranteed delivery). Payment for such Shares is to be made promptly by Purchaser in accordance with the terms of the Offer. The depositary for the Offer has advised Parent and Purchaser that, as of the expiration of the Offer, a total of approximately 12,768,787 Shares were validly tendered to Purchaser and not withdrawn (including approximately 341,056 Shares delivered through notices of guaranteed delivery), representing approximately 94.18% of the Shares outstanding. Shares tendered through notices of guaranteed delivery are required to be delivered to the depositary for the Offer within three trading days after the date of execution of the notice of guaranteed delivery. Parent has announced that it expects to complete the acquisition of the Company by means of a short-form merger of Purchaser with and into the Company in the next several days, without the need for a vote or meeting of Company shareholders. As a result of such merger, the Company will become a wholly owned subsidiary of Parent.
     On March 21, 2008, Parent issued a press release announcing the successful completion of the Offer. The full text of the press release issued by Parent is set forth as Exhibit (a)(12) hereto and is incorporated herein by reference.

 

Table of Contents

ITEM 9. EXHIBITS
     Item 9 of the Statement is hereby amended and supplemented by adding the following exhibit:
     
Exhibit   Description
(a)(12)
  Press Release issued by SBT Holdings Inc. and SBT Acquisition Inc. on March 21, 2008 (incorporated by reference to Exhibit (a)(1)(J) to the Schedule TO-T/A filed by SBT Acquisition Inc., SBT Holdings Inc. and Warburg Pincus Private Equity IX, L.P. on March 21, 2008)

 

Table of Contents

SIGNATURES
     After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
         
  LIFECORE BIOMEDICAL, INC.
 		  
  By:   /s/ Dennis J. Allingham    
    Dennis J. Allingham   
    President and Chief Executive Officer   
 
     Date: March 21, 2008

 

Table of Contents

INDEX TO EXHIBITS
     
Exhibit No.    
 
    
Exhibit (a)(1)*
  Offer to Purchase dated February 21, 2008 (incorporated by reference to Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO, filed by Parent and Purchaser with respect to the Company on February 21, 2008 (the “Schedule TO”))
 
    
Exhibit (a)(2)*
  Letter of Transmittal dated February 21, 2008 (incorporated by reference to Exhibit (a)(1)(B) to the Schedule TO)
 
    
Exhibit (a)(3)*
  Press Release issued by the Company dated January 15, 2008 (incorporated by reference to the Schedule 14D-9C of the Company filed on January 15, 2008) and Transcript of conference call by the Company on January 15, 2008 relating to the proposed acquisition of the Company by Parent (incorporated by reference to the Schedule 14D-9C of the Company filed on January 15, 2008)
 
    
Exhibit (a)(4)*
  Press Release issued by the Company dated February 14, 2008 (incorporated by reference to the Schedule TO-C filed by the Company on February 14, 2008)
 
    
Exhibit (a)(5)*
  Press Release issued by Parent and Purchaser dated January 15, 2008 (incorporated by reference to the Schedule TO-C filed by the Company on January 15, 2008)
 
    
Exhibit (a)(6)*
  Summary Advertisement published in The New York Times dated February 21, 2008 (incorporated by reference to Exhibit (a)(1)(I) to the Schedule TO)
 
    
Exhibit (a)(7)*
  Letter to Shareholders of the Company dated February 21, 2008
 
    
Exhibit (a)(8)*
  Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(D) to the Schedule TO)
 
    
Exhibit (a)(9)*
  Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(E) to the Schedule TO)
 
    
Exhibit (a)(10)*
  Notice of Guaranteed Delivery (incorporated by reference to Exhibit (a)(1)(C) to the Schedule TO)
 
    
Exhibit (a)(11)*
  Memorandum from the Company to all Option Holders dated February 26, 2008

 

Table of Contents

     
Exhibit No.    
 
    
Exhibit (a)(12)
  Press Release issued by SBT Holdings Inc. and SBT Acquisition Inc. on March 21, 2008 (incorporated by reference to Exhibit (a)(1)(J) to the Schedule TO-T/A filed by SBT Acquisition Inc., SBT Holdings Inc. and Warburg Pincus Private Equity IX, L.P. on March 21, 2008)
 
    
Exhibit (e)(1)*
  Opinion of Piper Jaffray & Co. dated February 14, 2008 (incorporated by reference to Annex B of this Schedule 14D-9)
 
    
Exhibit (e)(2)*
  Agreement and Plan of Merger dated as of January 15, 2008, among Parent, Purchaser and the Company (incorporated by reference to Exhibit (d)(1)(A) to the Schedule TO)
 
    
Exhibit (e)(3)*
  The Information Statement of the Company dated as of February 21, 2008 (incorporated by reference to Annex A of this Schedule 14D-9)
 
    
Exhibit (e)(4)*
  Confidentiality Agreement between Parent and the Company dated July 21, 2006 (incorporated by reference to Exhibit (d)(1)(C) to the Schedule TO)
 
    
Exhibit (e)(5)*
  Form of Change in Control Agreement between the Company and certain executive officers of the Company (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2004)
 
    
Exhibit (e)(6)*
  Change in Control Agreement dated June 17, 2004, between the Company and Dennis J. Allingham (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2004)
 
    
Exhibit (g)*
  None
 
*   Previously filed.

 

-----END PRIVACY-ENHANCED MESSAGE-----